Parker Waichman LLP

BMJ Highlights Flaws with Pradaxa’s Approval Route, Pushes Dose Monitoring

The British Medical Journal has published three reports and one editorial criticizing the way Pradaxa (dabigatran) was approved, and is advising drug dosing in the interest of patient safety. Boehringer Ingelheim’s Pradaxa is prescribed to patients who have nonvalvular atrial fibrillation (AF). The drug was the first new oral anticoagulant to hit the market in […]

Pradaxas-Approval-Route-Pushes-Dose-MonitoringThe British Medical Journal has published three reports and one editorial criticizing the way Pradaxa (dabigatran) was approved, and is advising drug dosing in the interest of patient safety.

Boehringer Ingelheim’s Pradaxa is prescribed to patients who have nonvalvular atrial fibrillation (AF). The drug was the first new oral anticoagulant to hit the market in an effort to supersede warfarin, an older anticoagulant. One of Pradaxa’s main selling points was that, unlike warfarin, it does not require drug monitoring. The BMJ reports allege that the manufacturer hid information showing that monitoring would significantly benefit the safety profile of the drug in order to maintain this claim.

Concerns about bleeding risks have plagued Pradaxa since it has been on the market. Pradaxa-related bleeding is particularly dangerous because there is no reversal agent, meaning that life-threatening hemorrhages cannot be remedied.

According to the BMJ reports, BI hid evidence from its own analysis showing that patients would have a significantly lower risk of bleeding if they underwent monitoring. Instead of making this information known to regulators, however, the drug maker hid data showing that drug monitoring “has the potential to provide patients an even better efficacy and safety profile than fixed-dose dabigatran and also a better safety and efficacy profile than a matched warfarin group.”

The BMJ reports said there were flaws in the “design and oversight” of the phase 3 trial, RE-LY. The reports also stated that there was “a potentially higher bleeding risk with dabigatran than has been stated” in the trial. The authors criticized the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), although less severely, for putting Pradaxa on the market through an expedited process or despite incomplete data.

Dr. Deborah Cohen, BMJ editor who authored some of the reports pointed out that “The US agency had concerns over misreporting of events” with Pradaxa and the company’s application for the drug was initially denied.

 “The BMJ has learnt that it has taken three reviews of the data to calculate the number of major and fatal bleeds among trial participants, and even today there are doubts whether all events have been properly accounted for.” Cohen said.

What Our Clients Say About Us
We have worked with thousands of clients and we appreciate them and their positive reviews. Here are just a few recent client reviews...
5 Star Reviews 150
karen otto
5 years ago
5 Star Reviews 150
Michelle Josama was very helpful and informative through our process. She was very friendly and made us feel very comfortable asking questions!
Irma Inez Sayz
5 years ago
5 Star Reviews 150
I have no words to express how grateful I am for the service of the Parker Waichman firm. Thanks to Michelle Josama and Jorge Peniche for all their attention.
Miguela Quezada
a month ago

Why Choose Us to Help You?

We Take Care of Everything
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
No Recovery = No Legal Fees
We work on a contingency-fee basis, meaning that we only get paid from a portion of your settlement or jury award. If you don't get compensation, you owe us nothing.
Decades of Experience
Your situation is stressful enough: Let us take on the deadlines, paperwork, investigation, and litigation. We'll handle every detail so you don't have to worry.
Respected by Our Peers
Judges, insurance adjusters, and fellow attorneys all speak highly of our skills, and we've earned numerous accolades, including a flawless rating from AVVO.
We Have Many Locations To Serve You
We have the experience and the skilled litigators to win your case. Contact us and speak with a real attorney who can help you.
Long Island – Nassau
Parker Waichman LLP
6 Harbor Park Drive
Port Washington, NY 11050
Long Island – Suffolk
Parker Waichman LLP
201 Old Country Road – Suite 145
Melville, NY 11747
New York
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038
Queens
Parker Waichman LLP
118-35 Queens Boulevard, Suite 400
Forest Hills, NY 11375
Brooklyn
Parker Waichman LLP
300 Cadman Plaza West
One Pierrepont Plaza, 12th Floor
Brooklyn, NY 11201
New Jersey
Parker Waichman LLP
80 Main Street, Suite 265
West Orange, NJ 07052
Florida
Parker Waichman LLP
27299 Riverview Center Boulevard
Suite 108
Bonita Springs, FL 34134
Nationwide Service
Parker Waichman LLP
59 Maiden Lane, 6th Floor
New York, NY 10038